Table 2 Comparisons of laboratory data and BMD measurements of children with chronic hepatitis B treated with IFN-alpha alone or combination with lamivudine and healthy controls.
Variables | Patients (n = 54) | Control (n = 50) | P |
|---|---|---|---|
TNF-α | 25.54 ± 8.30 | 15.47 ± 6.77 | NS |
IL-1β | 7.32 ± 12.13 | 5.48 ± 6.14 | NS |
IL-2r | 1403.07 ± 455.67 | 1120.48 ± 492.37 | 0.002 |
IL-6 | 25.21 ± 39.27 | 5.98 ± 6.49 | 0.001 |
IL-8 | 18.46 ± 14.77 | 12.55 ± 7.36 | 0.013 |
PTH | 41.51 ± 28.80 | 33.08 ± 18.22 | 0.029 |
s-CTX | 1.92 ± 0.76 | 1.61 ± 0.52 | 0.021 |
Osteocalcin | 64.67 ± 30.63 | 75.81 ± 31.10 | NS |
Serum calcium | 9.57 ± 1.83 | 9.49 ± 1.52 | NS |
ALP | 221.27 ± 67.27 | 219.66 ± 78.74 | NS |
ALT | 62.14 ± 88.31 | 27.01 ± 42.41 | 0.009 |
AST | 58.41 ± 65.57 | 31.72 ± 29.69 | 0.007 |
L2–4 BMD | 0.62 ± 0.13 | 0.59 ± 0.12 | NS |
Femur neck BMD | 0.80 ± 0.16 | 0.72 ± 0.15 | 0.012 |
Trochanter BMD | 0.68 ± 0.14 | 0.62 ± 0.14 | 0.046 |